Literature DB >> 20643518

Rationale for and preliminary results of proton beam therapy for mediastinal lymphoma.

Jing Li1, Bouthaina Dabaja, Valerie Reed, Pamela K Allen, Haihong Cai, Mayankkumar V Amin, John A Garcia, James D Cox.   

Abstract

PURPOSE: To evaluate the potential of three-dimensional proton beam therapy (3D-PBT) for reducing doses to normal structures in patients with mediastinal lymphomas compared with conventional photon radiation therapy (RT). METHODS AND MATERIALS: We treated 10 consecutive patients with mediastinal masses from lymphomas with 3D-PBT between July 2007 and February 2009 to 30.6-50.4 cobalt-Gray equivalents (CGE). Of those patients, 7 had primary refractory or recurrent disease, and 8 had Hodgkin lymphoma. Dosimetric endpoints were compared with those from conventional RT plans.
RESULTS: PBT delivered lower mean doses to the lung (6.2 vs. 9.5 Gy), esophagus (9.5 vs. 22.3 Gy), and heart (8.8 vs. 17.7 Gy) but not the breasts (5.9 vs. 6.1 Gy) than did conventional RT. Percentages of lung, esophagus, heart, and coronary artery (particularly the left anterior descending artery) volumes receiving radiation were consistently lower in the 3D-PBT plans over a wide range of radiation doses. Of the 7 patients who had residual disease on positron emission tomography before PBT, 6 (86%) showed a complete metabolic response.
CONCLUSIONS: In patients with mediastinal lymphomas, 3D-PBT produced significantly lower doses to the lung, esophagus, heart, and coronary arteries than did the current conventional RT. These lower doses would be expected to reduce the risk of late toxicities in these major organs.
Copyright © 2011. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20643518     DOI: 10.1016/j.ijrobp.2010.05.007

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  16 in total

Review 1.  Proton therapy for Hodgkin lymphoma.

Authors:  Michael S Rutenberg; Stella Flampouri; Bradford S Hoppe
Journal:  Curr Hematol Malig Rep       Date:  2014-09       Impact factor: 3.952

Review 2.  Optimal Therapy for Early-Stage Hodgkin's Lymphoma: Risk Adapting, Response Adapting, and Role of Radiotherapy.

Authors:  Andrea Riccardo Filippi; Mario Levis; Rahul Parikh; Bradford Hoppe
Journal:  Curr Oncol Rep       Date:  2017-05       Impact factor: 5.075

3.  Hodgkin lymphoma, version 2.2015.

Authors:  Richard T Hoppe; Ranjana H Advani; Weiyun Z Ai; Richard F Ambinder; Patricia Aoun; Celeste M Bello; Cecil M Benitez; Philip J Bierman; Kristie A Blum; Robert Chen; Bouthaina Dabaja; Andres Forero; Leo I Gordon; Francisco J Hernandez-Ilizaliturri; Ephraim P Hochberg; Jiayi Huang; Patrick B Johnston; Nadia Khan; David G Maloney; Peter M Mauch; Monika Metzger; Joseph O Moore; David Morgan; Craig H Moskowitz; Carolyn Mulroney; Matthew Poppe; Rachel Rabinovitch; Stuart Seropian; Christina Tsien; Jane N Winter; Joachim Yahalom; Jennifer L Burns; Hema Sundar
Journal:  J Natl Compr Canc Netw       Date:  2015-05       Impact factor: 11.908

4.  New strategies in radiation therapy: exploiting the full potential of protons.

Authors:  Radhe Mohan; Anita Mahajan; Bruce D Minsky
Journal:  Clin Cancer Res       Date:  2013-09-27       Impact factor: 12.531

Review 5.  Charged particle therapy--optimization, challenges and future directions.

Authors:  Jay S Loeffler; Marco Durante
Journal:  Nat Rev Clin Oncol       Date:  2013-05-21       Impact factor: 66.675

Review 6.  Novel radiotherapy techniques for involved-field and involved-node treatment of mediastinal Hodgkin lymphoma: when should they be considered and which questions remain open?

Authors:  Frank Lohr; Dietmar Georg; Luca Cozzi; Hans Theodor Eich; Damien C Weber; Julia Koeck; Barbara Knäusl; Karin Dieckmann; Yasser Abo-Madyan; Christian Fiandra; Rolf-Peter Mueller; Andreas Engert; Umberto Ricardi
Journal:  Strahlenther Onkol       Date:  2014-09-11       Impact factor: 3.621

7.  Proton therapy for adults with mediastinal lymphomas: the International Lymphoma Radiation Oncology Group guidelines.

Authors:  Bouthaina Shbib Dabaja; Bradford S Hoppe; John P Plastaras; Wayne Newhauser; Katerina Rosolova; Stella Flampouri; Radhe Mohan; N George Mikhaeel; Youlia Kirova; Lena Specht; Joachim Yahalom
Journal:  Blood       Date:  2018-08-14       Impact factor: 22.113

8.  Proton Therapy: Ever Shifting Sands and the Opportunities and Obligations within.

Authors:  Christine E Hill-Kayser; Stefan Both; Zelig Tochner
Journal:  Front Oncol       Date:  2011-09-06       Impact factor: 6.244

Review 9.  Cardiotoxicity of mediastinal radiotherapy.

Authors:  Ivica Ratosa; Maja Ivanetic Pantar
Journal:  Rep Pract Oncol Radiother       Date:  2019-10-30

10.  Hodgkin's lymphoma emerging radiation treatment techniques: trade-offs between late radio-induced toxicities and secondary malignant neoplasms.

Authors:  Laura Cella; Manuel Conson; Maria Cristina Pressello; Silvia Molinelli; Uwe Schneider; Vittorio Donato; Roberto Orecchia; Marco Salvatore; Roberto Pacelli
Journal:  Radiat Oncol       Date:  2013-01-30       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.